Form 4: Mersana Director Sells All Shares Post-Merger

Mersana Therapeutics director Kristen Hege reported the disposition of all her common stock and stock options following the company's merger with Day One Biopharmaceuticals.

Summary

• Kristen Hege, a director of Mersana Therapeutics, Inc., reported the disposition of all her beneficial ownership in the company's common stock and stock options.
• The transactions occurred on January 6, 2026, coinciding with the effective date of the merger between Mersana Therapeutics and Day One Biopharmaceuticals, Inc.
• Mersana Therapeutics became a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc. following the merger.
• Shareholders of Mersana Therapeutics received $25.00 per share in upfront cash and one non-tradeable Contingent Value Right (CVR) per share.
• Each CVR represents the right to receive up to an additional $30.25 in cash upon the achievement of specified milestones.
• Stock options with an exercise price less than the upfront cash consideration were cashed out for the Offer Price minus the exercise price.
• Out-of-the-money stock options (exercise price equal to or greater than the upfront cash consideration) were cancelled if not exercised by a specified date prior to the merger.

Sentiment

Score: 6

Explanation: The filing reports the completion of a merger, which provides a definitive outcome for shareholders. The combination of upfront cash and potential CVR payments offers a structured exit, though the CVRs introduce future uncertainty and are non-tradeable. For the reporting person, it's a complete disposition of holdings due to the company's acquisition.

Positives

• Mersana Therapeutics shareholders received a definitive cash payment of $25.00 per share as part of the merger consideration.
• Shareholders also received Contingent Value Rights (CVRs) offering potential additional payments of up to $30.25 per CVR, providing upside potential based on future milestone achievements.
• The merger provides a clear exit strategy and liquidity event for investors in Mersana Therapeutics.

Negatives

• Out-of-the-money stock options were cancelled without consideration if not exercised by the specified Last Exercise Date prior to the merger.
• The Contingent Value Rights (CVRs) are non-tradeable, limiting liquidity and requiring holders to wait for milestone achievements for potential payments.
• Mersana Therapeutics is no longer an independent publicly traded entity, removing it from public market investment opportunities.

Risks

• The contingent value rights (CVRs) are subject to the achievement of specific milestones, meaning the full potential payment of $30.25 per CVR is not guaranteed.
• The CVRs are non-tradeable, which means holders cannot sell them on the open market and must rely on the acquirer's efforts to achieve the underlying milestones.

Future Outlook

The completion of the merger means Mersana Therapeutics is now a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc., concluding its independent public entity status. The future value for former Mersana shareholders holding CVRs depends entirely on the achievement of specified milestones outlined in the contingent value rights agreement.

Industry Context

This transaction represents a consolidation event within the biopharmaceutical industry, where a publicly traded company (Mersana) is acquired by another entity (Day One Biopharmaceuticals). Such mergers are common for companies seeking to expand their pipeline, market share, or achieve synergies. The use of Contingent Value Rights (CVRs) is a frequent mechanism in biotech acquisitions to bridge valuation gaps and share future development risks and rewards, particularly for pipeline assets.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biopharmaceutical mergers is a standard practice, often seen in deals where the acquired company has pipeline assets with significant but uncertain future value. For example, similar structures have been used in acquisitions like Celgene by Bristol-Myers Squibb (for ozanimod and liso-cel) or various smaller biotech acquisitions.
• The combination of upfront cash consideration with CVRs provides a blended valuation approach, common in biotech M&A, allowing the acquirer to mitigate risk while offering potential upside to the target's shareholders based on future performance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received upfront cash and CVRs for their shares, ending their direct equity ownership in Mersana and transitioning to a new investment vehicle for contingent payments.
• Employees: Likely subject to integration plans and potential changes in roles or reporting structures under Day One Biopharmaceuticals' ownership.
• Management: The director (Kristen Hege) has disposed of all holdings, indicating a change in her direct relationship with the now-private entity.

Next Steps

• Former Mersana shareholders holding CVRs will await the achievement of specified milestones for potential additional cash payments.
• Day One Biopharmaceuticals, Inc. will proceed with the integration of Mersana Therapeutics as a wholly-owned subsidiary.

Key Dates

Keywords

Mersana Therapeutics, Day One Biopharmaceuticals, Merger, Form 4, Insider Trading, Stock Options, Contingent Value Rights, MRSN, Acquisition, Biopharmaceuticals